3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness

Cellular Product Infusion Protocols & Acute Reaction Management

Core Clinical Principle: Product administration is the last link in a donor/patient-to-product-to-recipient chain. The nurse protects identity, viability, route, compatibility, and patient stability by following the current product label, controlled cellular-therapy SOP, release documents, and order. Equipment, filters, thaw location, rate, flush, monitoring intervals, and verifier roles are product-specific; a familiar blood-component routine must not be substituted.

1. Pre-Administration Identity, Release, and Clinical Readiness

Use the SOP-defined verifier(s) and required patient identifiers to reconcile the patient, order, product label, donation or product identifier, intended recipient, source, manipulation, dose/volume, bag sequence, ABO/Rh considerations, expiration, storage state, and release status. Check accompanying records and every bag rather than assuming that one match covers the shipment. Resolve a discrepancy before thaw, connection, injection, or infusion; quarantine and escalate through the cellular laboratory/medical director process rather than relabeling at bedside.

Clinical readiness includes consent, vascular or procedural access, baseline assessment, ordered premedications, required rescue resources, and confirmation that the planned conditioning/lymphodepletion interval follows the specific regimen. There is no universal 24–48-hour washout: verify the protocol. Fever or active infection triggers urgent assessment, cultures and treatment as indicated, but the decision to delay a time-sensitive product is multidisciplinary and considers product stability and patient risk.

Inspect the container and overwrap for identity, integrity, leaks, clots/aggregates, abnormal appearance, temperature or shipping deviations, and expiration. Document custody handoffs and any deviation. Do not spike, pool, wash, split, relabel, or discard a cellular product unless the controlled procedure and authorized personnel permit it.

2. Equipment, Filter, Pump, Flush, and Thaw Decisions

The approved administration record should specify:

• Tubing and filter: Fresh marrow or PBSC products may use a standard blood administration filter to remove gross clots or debris. Commercial or investigational cellular products may prohibit leukocyte-depleting filters or require a dedicated set. A leukoreduction filter can remove the therapeutic leukocytes and must not be improvised. Nominal pore size alone does not prove compatibility.
• Pump, gravity, or syringe: Some products are infused by gravity or syringe; a pump is acceptable only when the product instructions and program have validated the device, pressure, tubing, and rate. Avoid claims that every pump mechanically destroys cells.
• Flush and concurrent fluids: Use only the solution and sequence authorized for that product and line. Normal saline is common, but “NS only for every cellular product” is not a universal rule. Confirm whether other medications/fluids must be stopped and whether a dedicated lumen is required.
• Thaw and time limit: Bedside, pharmacy, or cell-processing-lab thaw may all be valid. The thaw device, temperature, mixing, overwrap, expiration-after-thaw, and time to administration come from the product/manufacturer and SOP. Coordinate so the patient and team are ready before an irreversible thaw.
• Bag sequence and dose accounting: Record start/stop time, volume and cells delivered, residual or lost product, flush, reactions, and final disposition for every container.

3. CAR T-Cell Specific Infusion Readiness & Safety Protocols

Chimeric Antigen Receptor (CAR) T-cell products (e.g., Tisagenlecleucel, Axicabtagene ciloleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel, Idecabtagene vicleucel, Ciltacabtagene autoleucel) represent living, genetically modified cellular immunotherapies with distinct administration rules.

+---------------------------------------------------------------------------------------------------+
|                         CAR T-CELL LABEL & PROGRAM READINESS CHECKLIST                           |
|                                                                                                   |
|  1. TOCILIZUMAB AVAILABILITY CHECK (LABEL REQUIREMENT):                                           |
|     - Current CAR-T prescribing information directs the team to CONFIRM THAT 2 DOSES OF           |
|       THE LABEL-REQUIRED TOCILIZUMAB SUPPLY (weight-directed dosing, maximum per label) IS AVAILABLE           |
|       PRIOR TO INFUSION. This survives as a labeling requirement even though FDA eliminated       |
|       the CAR-T REMS programs on June 27, 2025 - do not confuse the two sources of the rule.      |
|                                                                                                   |
|  2. PREMEDICATION:                                                                                |
|     - Give the label/order-specific antipyretic and antihistamine when required; reconcile        |
|       allergies, prior doses, and agents that could mask a baseline fever.                         |
|                                                                                                   |
|  3. CORTICOSTEROID DISCIPLINE:                                                                    |
|     - Avoid routine prophylactic corticosteroids when the product label directs because they may  |
|       impair cellular activity. Corticosteroids are not absolutely forbidden: they are used for   |
|       ICANS, refractory CRS, anaphylaxis, and other indications under the current protocol.        |
|                                                                                                   |
|  4. POST-INFUSION MONITORING WINDOW (CURRENT LABELING):                                           |
|     - Monitor patients AT LEAST DAILY FOR 7 DAYS following infusion for Cytokine Release          |
|       Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).          |
|     - Instruct patients to remain WITHIN PROXIMITY OF A HEALTHCARE FACILITY FOR >= 2 WEEKS and    |
|       to AVOID DRIVING FOR >= 2 WEEKS after infusion.                                             |
+---------------------------------------------------------------------------------------------------+

4. Infusion Versus Injection and Regional Administration

Most hematopoietic grafts and current commercial CAR T products are administered intravenously, but the blueprint also includes injection management because investigational or product-specific cellular therapies may be delivered intratumorally, intralesionally, into a cavity, or through another regional route. Route is part of the product identity and order; an IV workflow cannot be improvised for an injection product.

Before administration, reconcile the patient and product identity, exact route/site, dose and volume, imaging or procedural requirements, device/needle/catheter compatibility, expiration and resuspension instructions, release criteria, consent, and emergency plan. Maintain asepsis and chain of custody, use required PPE, document each container and disposition, and monitor the site plus systemic vital/neurologic symptoms. Stop and escalate for route uncertainty, wrong-site risk, leakage/extravasation, unexpected resistance, product loss, or an acute reaction. Follow the label, trial protocol, pharmacy/cell-lab instructions, and credentialed procedural roles for the specific product.